CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration

Neoplasia

Volumn 9, Issue 7, 2007, Pages 556-562

  Loberg, Robert D ^a,b   Ying, Chi ^b   Craig, Matt ^b   Yan, Li ^c   Snyder, Linda A ^c   Pienta, Kenneth J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CENTOCOR INC   (United States)

Author keywords

Angiogenesis; Chemokine; Monocyte chemoattractant protein 1; Prostate cancer; Tumor associated macrophage

Indexed keywords

C 1142; C 1322; CD68 ANTIGEN; CNTO 888; HULGG ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CELL INFILTRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IN VIVO STUDY; MACROPHAGE; MALE; METASTASIS; MICROENVIRONMENT; MONOCYTE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SCID MOUSE; TUMOR VOLUME;

EID: 34547184682     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.07307     Document Type: Article

References (15)

1. Taichman RS, Cooper C, Kelller ET, Pienta KJ, Taichman NS, and McCauley LK (2002). Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62 (6), 1832-1837.
2. Vanderkerken K, Vande Broek I, Eizirik DL, Van Valckenborgh E, Asosingh K, Van Riet I, and Van Camp B (2002). Monocyte chemoattractant protein-1 (MCP-1), secreted by bone marrow endothelial cells, induces chemoattraction of 5Tmultiplemyeloma cells. Clin Exp Metastasis 19 (1), 87-90.
3. Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukadia N, Haruma K, and Chayama K (2002). Monocyte chemoattractant protein-1 expression correlates withmacrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer 102 (3), 220-224.
4. Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, and Jonjic N (1998). Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract 194 (5), 335-340.
5. Lebrecht A, Grimm C, Lantzsch T, Ludwig E, Hefler L, Ulbrich E, and Koelbl H (2004). Monocyte chemoattractant protein-1 serum levels in patients with breast cancer. Tumour Biol 25 (1-2), 14-17.
6. Loberg RD, Day LL, Harwood J, Ying C, St John LN, Giles R, Neely CK, and Pienta KJ (2006). CCL2 is a potent regulator of prostate cancer cell migration and proliferation. Neoplasia 8 (7), 578-586.
7. Lu Y, Cal Z, Galson DL, Xiao G, Liu Y, George DE, Melhem MF, Yao Z, and Zhang J (2006). Monocyte chemotactic protein-1 (MCP-1) acts as a paracrine and autocrine factor for prostate cancer growth and invasion. Prostate 66 (12), 1311-1318.
8. Korenchuk S, Lehr JE, MClean L, Lee YG, Whitney S, Vessella R, Lin DL, and Pienta KJ (2001). VCaP, a cell-based model system of human prostate cancer. In Vivo 15 (2), 163-168.
9. Loberg RD, St John LN, Day LL, Neeley CK, and Pienta KJ (2006). Development of the VCaP androgen-independent model of prostate cancer. Urol Oncol 24 (2), 161-168.
10. Zhou JR, Yu L, Zerbini LF, Libermann TA, and Blackburn GL (2004). Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 110 (6), 800-806.
11. Lu Y, Cai Z, Xiao G, Keller ET, Mizokami A, Yao Z, Roodman GD, and Zhang J (2007). Monocyte chemotactic protein-1 mediates prostate cancer-induced bone resorption. Cancer Res 67 (8), 3646-3653.
12. Balkwill F and Mantovani A (2001). Inflammation and cancer: back to Virchow? Lancet 357 (9255), 539-545.
13. Coussens LM and Werb Z (2002). Inflammation and cancer. Nature 420 (6917), 860-867.
14. Lu H, Ouyang W, and Huang C (2006). Inflammation, a key event in cancer development. Mol Cancer Res 4 (4), 221-233.
15. Loberg RD, Bradley DA, and Pienta KJ (in press). The lethal phenotype of cancer: the molecular basis of death due to malignancy. Cancer.